secwatch.observer — SEC 8-K summary
======================================

Issuer:     MYRIAD GENETICS INC (MYGN)
CIK:        0000899923
Form:       8-K
Filed at:   2026-05-05T23:59:59+00:00
Accession:  0000899923-26-000036
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Myriad Genetics Q1 revenue $200.4M, GAAP net loss $34.1M; reiterates FY guidance
--------------------------------------------------------------------------------

- GAAP net loss $34.1M ($0.36/sh); adjusted loss $0.09/sh; adjusted EBITDA negative $4.5M.
- Revenue $200.4M (+2% YoY); Cancer Care +4%, Prenatal -15%, Mental Health +24%.
- Test volumes 385k flat YoY; Cancer Care +13%, Prenatal -12%, Mental Health +7%.
- Launched Precise MRD (ultrasensitive assay) and received FDA approval for MyChoice CDx as Zejula companion diagnostic.
- Reiterated FY 2026 guidance: revenue $860-880M, adjusted EBITDA $37-49M, adj. gross margin 68-69%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/899923/000089992326000036/0000899923-26-000036-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/899923/000089992326000036/mygn-20260505.htm
  HTML page:      https://secwatch.observer/filing/0000899923-26-000036

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer